Source: Frontiers in Cellular and Infection Microbiology. Unidade: FMRP
Subjects: LEISHMANIOSE VISCERAL, QUIMIOTERAPIA ADJUVANTE, FARMACOTERAPIA, INTERLEUCINA 10, LEUCÓCITOS MONONUCLEARES
ABNT
MAGALHÃES, Lucas Sousa et al. Use of N-acetylcysteine as treatment adjuvant regulates immune response in visceral leishmaniasis: Pilot clinical trial and in vitro experiments. Frontiers in Cellular and Infection Microbiology, v. 12, 2022Tradução . . Disponível em: https://doi.org/10.3389/fcimb.2022.1045668. Acesso em: 20 ago. 2024.APA
Magalhães, L. S., Melo, E. V., Damascena, N. P., Albuquerque, A. C. B., Santos, C. N. O., Rebouças, M. C., et al. (2022). Use of N-acetylcysteine as treatment adjuvant regulates immune response in visceral leishmaniasis: Pilot clinical trial and in vitro experiments. Frontiers in Cellular and Infection Microbiology, 12. doi:10.3389/fcimb.2022.1045668NLM
Magalhães LS, Melo EV, Damascena NP, Albuquerque ACB, Santos CNO, Rebouças MC, Bezerra M de O, Silva RL da, Oliveira FA de, Santos PL, Silva JS da, Lipscomb MW, Silva ÂM da, Jesus AR de, Almeida RP de. Use of N-acetylcysteine as treatment adjuvant regulates immune response in visceral leishmaniasis: Pilot clinical trial and in vitro experiments [Internet]. Frontiers in Cellular and Infection Microbiology. 2022 ; 12[citado 2024 ago. 20 ] Available from: https://doi.org/10.3389/fcimb.2022.1045668Vancouver
Magalhães LS, Melo EV, Damascena NP, Albuquerque ACB, Santos CNO, Rebouças MC, Bezerra M de O, Silva RL da, Oliveira FA de, Santos PL, Silva JS da, Lipscomb MW, Silva ÂM da, Jesus AR de, Almeida RP de. Use of N-acetylcysteine as treatment adjuvant regulates immune response in visceral leishmaniasis: Pilot clinical trial and in vitro experiments [Internet]. Frontiers in Cellular and Infection Microbiology. 2022 ; 12[citado 2024 ago. 20 ] Available from: https://doi.org/10.3389/fcimb.2022.1045668